Oxidative cytotoxic agent withaferin a resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 604-617

  Grogan, Patrick T ^a,b   Sarkaria, Jann N ^c   Timmermann, Barbara N ^d   Cohen, Mark S ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

Akt mTOR pathway; Glioblastoma multiforme; Heat shock response; O6 methylguanine DNA methyltransferase; Oxidative stress; Temozolomide resistance; Withaferin A

Indexed keywords

ACETYLCYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK TRANSCRIPTION FACTOR 1; HEME OXYGENASE 1; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; S6 KINASE; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; WITHAFERIN A; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; HMOX1 PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN; WITHANOLIDE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME DEGRADATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HEAT SHOCK RESPONSE; HUMAN; HUMAN CELL; MISMATCH REPAIR; MONOTHERAPY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; G2 PHASE CELL CYCLE CHECKPOINTS; GLIOBLASTOMA; HEME OXYGENASE-1; HUMANS; MAP KINASE SIGNALING SYSTEM; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; WITHANOLIDES;

EID: 84904557231     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0084-7     Document Type: Article

References (73)

1. ACS (2013) Cancer facts and figures 2013. American Cancer Society, Atlanta [cited 2013 November 20]
2. Gillingham FJ, Yamashita J (1975) The effect of radiotherapy for glioblastoma: a review of 516 cases (author 's transl). No Shinkei Geka 3(4):329-336
3. Onoyama Y et al (1976) Radiation therapy in the treatment of glioblastoma. AJR Am J Roentgenol 126(3):481-492
4. Sheline GE (1977) Radiation therapy of brain tumors. Cancer 39(2 Suppl):873-881
5. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996 (Pubitemid 40349501)
6. Stupp R et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20(5):1375-1382 (Pubitemid 34177445)
7. DeAngelis LM (2005) Chemotherapy for brain tumors - a new beginning. N Engl J Med 352(10):1036-1038
8. Taphoorn MJ et al (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6(12):937-944 (Pubitemid 41685226)
9. Chamberlain MC et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81-83
10. Paz MF et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10(15):4933-4938 (Pubitemid 39099766)
11. Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003 (Pubitemid 40349502)
12. Hansen RJ et al (2007) Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis 28(5):1111-1116 (Pubitemid 47072198)
13. Kitange GJ et al (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11(3):281-291
14. Quick A et al (2010) Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5(1):14-27
15. Chamberlain MC (2010) Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10(10):1537-1544
16. Zhang J, Stevens MF, Bradshaw TD(2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5(1):102-114
17. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492-507
18. Zhang H et al (2013) Antiproliferative withanolides from Datura wrightii. J Nat Prod 76(3):445-449
19. Santagata S et al (2012) Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol 7(2):340-349
20. Hahm ER et al (2011) Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. Plos One 6(8):e23354
21. Mayola E et al (2011) Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 16(10):1014-1027
22. Widodo N et al (2010) Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling. PLoS ONE 5(10):e13536
23. Malik F et al (2007) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis 12(11):2115-2133 (Pubitemid 47498235)
24. Oh JH, Kwon TK (2009) Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol 9(5):614-619
25. Koduru S et al (2010) Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther 9(1):202-210
26. Yu Y et al (2010) Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 79(4):542-551
27. Stan SD, Zeng Y, Singh SV (2008) Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer 60(Suppl 1):51-60
28. Oh JH et al (2008) Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis 13(12):1494-1504
29. Mandal C et al (2008) Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis 13(12):1450-1464
30. Mohan R et al (2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7(2):115-122 (Pubitemid 39491728)
31. Singh D et al (2007) Withania somnifera inhibits NF-kappaB and AP-1 transcription factors in human peripheral blood and synovial fluid mononuclear cells. Phytother Res 21(10):905-913 (Pubitemid 47582762)
32. Samadi AK et al (2010) A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo. Surgery 148(6):1228-1236, discussion 1236
33. Shah N et al (2009) Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells: combinational approach for enhanced differentiation. Cancer Sci 100(9):1740-1747
34. Grogan PTet al (2013) Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs 31(3):545-557
35. Yang HJ, Shi GQ, Dou QP (2007) The tumor proteasome is a primary target for the natural anticancer compound withaferin a isolated from "Indian Winter Cherry". Mol Pharmacol 71(2):426-437
36. Stan SD et al (2008) Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 68(18):7661-7669
37. Devi PU, Kamath R, Rao BS (2000) Radiosensitization of a mouse melanoma bywithaferin A: in vivo studies. Indian J Exp Biol 38(5):432-437 (Pubitemid 30368821)
38. Samadi AK et al (2012) Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumor Biol 33(4):1179-1189
39. Fong MYet al (2012) Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One 7(7):e42265
40. Munagala R et al (2011) Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 32(11):1697-1705
41. Nadkarni A et al (2012) ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J Neurooncol 110(3):349-357
42. Samadi AK et al (2010) Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma. J Nat Prod 73(9):1476-1481
43. Samadi AK et al (2011) A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Lett 312(2):158-167
44. Ryu CH et al (2012) Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol 2012:987495
45. Puputti M et al (2006) Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 4(12):927-934 (Pubitemid 46121551)
46. Wullich B et al (1993) Amplified met gene linked to double minutes in human glioblastoma. Eur J Cancer 29A(14):1991-1995 (Pubitemid 23324360)
47. Berezowska S, Schlegel J (2011) Targeting ErbB receptors in highgrade glioma. Curr Pharm Des 17(23):2468-2487
48. Potti A et al (2004) Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest 22(4):537-544 (Pubitemid 39506874)
49. Guessous F et al (2010) An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem 10(1):28-35
50. Zhang WB et al (2010) Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285(52):40461-40471
51. Ansari N, Khodagholi F, Amini M (2011) 2-Ethoxy-4,5-diphenyl-1, 3-oxazine-6-one activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Eur J Pharmacol 658(2-3):84-90
52. Qiao S et al (2012) Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes. Biochem Pharmacol 83(9):12
53. Khan S, Rammeloo AW, Heikkila JJ (2012) Withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance. PLoS One 7(11):e50547
54. D'Atri S et al (2000) Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294(2):664-671 (Pubitemid 30490843)
55. Hirose Yet al (2003) Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg 98(3):591-598
56. Weller M et al (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77(12):1156-1164
57. Sztajnkrycer MD (2002) Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40(6):789-801
58. Baer JC et al (1993) Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67(6):1299-1302 (Pubitemid 23172868)
59. Kaina B, Margison GP, Christmann M (2010) Targeting O(6)-methylguanine- DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 67(21):3663-3681
60. Zheng M et al (2008) Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther 7(12):3842-3851
61. Citti L et al (1996) Targeting of O6-methylguanine-DNA methyltransferase (MGMT) activity by antimessenger oligonucleotide sensitizes CHO/Mex+ transfected cells to mitozolomide. Carcinogenesis 17(1):25-29 (Pubitemid 26091266)
62. Kreth S et al (2013) In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol 125(5):671-681
63. Xie SM et al (2011) Silencing of MGMT with small interference RNA reversed resistance in human BCUN-resistant glioma cell lines. Chin Med J (Engl) 124(17):2605-2610
64. Strik HM et al (2012) Temozolomide dosing regimens for glioma patients. Curr Neurol Neurosci Rep 12(3):286-293
65. Rogakou EP et al (2000) Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 275(13):9390-9395 (Pubitemid 30185164)
66. Grover A et al (2011) Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinforma 12(Suppl 1):S30
67. Fu J et al (2010) Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro-Oncology 12(4):328-340
68. Laurent A et al (2005) Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65(3):948-956 (Pubitemid 40216456)
69. Cabello CM, Bair WB 3rd, Wondrak GT (2007) Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 8(12):1022-1037 (Pubitemid 350224328)
70. Lee JJ et al (2011) PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 18(4):666-677
71. Koul D (2008) PTEN signaling pathways in glioblastoma. Cancer Biology & Therapy 7(9):1321-1325
72. Lino MM, Merlo A (2011) PI3Kinase signaling in glioblastoma. J Neurooncol 103(3):417-427
73. Wu J et al (2011) Vitamin K3-2,3-epoxide induction of apoptosis with activation of ROS-dependent ERK and JNK protein phosphorylation in human glioma cells. Chem Biol Interact 193(1):3-11